RxSight/$RXST

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About RxSight

RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.

Ticker

$RXST
Sector
Primary listing

Employees

498

RxSight Metrics

BasicAdvanced
$347M
-
-$0.80
1.15
-

What the Analysts think about RxSight

Analyst ratings (Buy, Hold, Sell) for RxSight stock.

Bulls say / Bears say

The installed base of Light Delivery Devices expanded 34% YoY to 1,084 units as of June 30, 2025, laying the groundwork for future consumable LAL revenue growth (Nasdaq).
RxSight’s gross margin improved to 74.9% in Q2 2025 from 69.5% in Q2 2024, driven by a favorable product mix shift toward higher-margin Light Adjustable Lens sales (Nasdaq).
During Q2 2025, RxSight launched its Light Adjustable Lens system in South Korea and Singapore and received FDA approval to expand the lens dioptric range, diversifying its market presence and regulatory footprint (TipRanks).
Full-year 2025 revenue guidance was cut dramatically to $120 million–$130 million from $160 million–$175 million, implying a 7%–14% YoY decline and underscoring significant headwinds in LDD adoption (Investopedia).
Second-quarter 2025 revenue of $33.6 million represented an 11% sequential drop from Q1 2025’s $37.9 million, signaling waning near-term demand for both LALs and LDDs (Nasdaq).
Light Delivery Device unit sales plunged 49% YoY to just 40 units in Q2 2025, highlighting execution challenges in expanding the device install base critical for recurring LAL consumable revenue (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 16 Oct 2025.

RxSight Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

RxSight Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RXST

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs